Just because the science is hard that doesn't mean that biotechnology firms won't conduct pioneering regenerative medicine research or that major pharmaceutical companies won't invest in cell therapies. Regulatory approval for new products and health care payer reimbursement for innovative treatments also are possible despite the novelty of the field.
Companies focus on hard science, long-term pay-off at stem cell meeting
Just because the science is hard that doesn't mean that biotechnology firms won't conduct pioneering regenerative medicine research or that major pharmaceutical companies won't invest in cell therapies. Regulatory approval for new products and health care payer reimbursement for innovative treatments also are possible despite the novelty of the field.
More from Alimentary/Metabolic
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.